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ABSTRACT
Background
The catalytically active 66-kDa subunit of the human immunodeficiency virus type 1 (HIV-1)
reverse transcriptase (RT) consists of DNA polymerase, connection, and ribonuclease H (RNase H)
domains. Almost all known RT inhibitor resistance mutations identified to date map to the
polymerase domain of the enzyme. However, the connection and RNase H domains are not
routinely analysed in clinical samples and none of the genotyping assays available for patient
management sequence the entire RT coding region. The British Columbia Centre for Excellence
in HIV/AIDS (the Centre) genotypes clinical isolates up to codon 400 in RT, and our retrospective
statistical analyses of the Centre’s database have identified an N348I mutation in the RT
connection domain in treatment-experienced individuals. The objective of this multidisciplinary
study was to establish the in vivo relevance of this mutation and its role in drug resistance.
Methods and Findings
The prevalence of N348I in clinical isolates, the time taken for it to emerge under selective
drug pressure, and its association with changes in viral load, specific drug treatment, and known
drug resistance mutations was analysed from genotypes, viral loads, and treatment histories
from the Centre’s database. N348I increased in prevalence from below 1% in 368 treatment-
naı ¨ve individuals to 12.1% in 1,009 treatment-experienced patients (p ¼ 7.7 3 10
 12). N348I
appeared early in therapy and was highly associated with thymidine analogue mutations (TAMs)
M41L and T215Y/F (p , 0.001), the lamivudine resistance mutations M184V/I (p , 0.001), and
non-nucleoside RTI (NNRTI) resistance mutations K103N and Y181C/I (p , 0.001). The association
with TAMs andNNRTI resistance mutations was consistentwith the selection ofN348I in patients
treated with regimens that included both zidovudine and nevirapine (odds ratio 2.62, 95%
confidence interval 1.43–4.81). The appearance of N348I was associated with a significant
increase in viral load (p , 0.001), which was as large as the viral load increases observed for any
of the TAMs. However, this analysis did not account for the simultaneous selection of other RT or
protease inhibitor resistance mutations on viral load. To delineate the role of this mutation in RT
inhibitor resistance, N348I was introduced into HIV-1 molecular clones containing different
genetic backbones. N348I decreased zidovudine susceptibility 2- to 4-fold in the context of wild-
type HIV-1 or when combined with TAMs. N348I also decreased susceptibility to nevirapine (7.4-
fold) and efavirenz (2.5-fold) and significantly potentiated resistance to these drugs when
combined with K103N. Biochemical analyses of recombinant RT containing N348I provide
supporting evidence for the role of this mutation in zidovudine and NNRTI resistance and give
some insight into the molecular mechanism of resistance.
Conclusions
This study provides the first in vivo evidence that treatment with RT inhibitors can select a
mutation (i.e., N348I) outside the polymerase domain of the HIV-1 RT that confers dual-class
resistance. Its emergence, which can happen early during therapy, may significantly impact on a
patient’s response to antiretroviral therapies containing zidovudine and nevirapine. This study
also provides compelling evidence for investigating the role of other mutations in the
connection and RNase H domains in virological failure.
The Editors’ Summary of this article follows the references.
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The advent of highly active antiretroviral therapy has
dramatically improved the clinical status of many HIV-
infected patients. However, one of the major contributing
factors to virological failure during highly active antiretro-
viral therapy is the selection and evolution of drug-resistant
HIV strains [1,2]. Accordingly, a better understanding of drug
resistance is needed to effectively prevent and manage
resistance.
HIV-1 reverse transcriptase (RT) catalyses the conversion
of the viral single-stranded genomic RNA into a double-
stranded proviral DNA precursor. Due to its essential role in
HIV replication, RT is a major target for chemotherapeutic
intervention. In this regard, 11 of the 24 anti–HIV-1
inhibitors approved by the US Food and Drug Administra-
tion are RT inhibitors (RTIs). These can be divided into two
therapeutic classes: (i) the nucleoside/nucleotide RT inhib-
itors (NRTIs), such as zidovudine (AZT) and lamivudine
(3TC), that bind in the active site of the RT and act as
competitive chain terminating inhibitors of DNA polymer-
isation [3]; and the non-nucleoside RT inhibitors (NNRTIs),
such as nevirapine (NVP) and efavirenz (EFV), that bind to a
nonactive site pocket in the HIV-1 RT (termed NNRTI-
binding pocket) and act as allosteric inhibitors of DNA
polymerisation [4–6].
HIV-1 RT is an asymmetric dimer that consists of a 66-kDa
(p66) subunit and a p66-derived 51-kDa (p51) subunit. The
catalytically active p66 subunit comprises the DNA polymer-
ase (residues 1–315), connection (residues 316–437), and
ribonuclease H (RNase H; residues 438–560) domains [7,8].
The polymerase domain can be further divided into the
ﬁngers, palm, and thumb subdomains [7,8]. Almost all RTI
resistance mutations identiﬁed to date map to the DNA
polymerase domain of RT, although this may be due in part
to the fact that the connection and RNase H domains are not
usually analysed in clinical samples [2,9]. In fact, none of the
genotyping or phenotyping assays currently available for
patient management assay the entire RT coding region, and
genotyping algorithms used to predict drug resistance are
generally conﬁned to the analysis of mutations in the ﬁrst 240
amino acids of the RT [9].
Recently, however, a growing body of evidence has
emerged that implicates mutations outside of the DNA
polymerase domain in RTI resistance. These include the
G333D/E polymorphism that facilitates dual AZT/3TC resist-
ance in viruses that contain both thymidine analogue
mutations (TAMs) and M184V [10,11] and the Y318F
mutation that confers NNRTI resistance [12]. A more recent
study that performed genotypic and phenotypic analyses
from a small number of NRTI-experienced and treatment-
naı ¨ve individuals demonstrated that the C-terminal domains
obtained from treatment-naı ¨ve patients did not increase AZT
resistance compared to wild-type (WT) virus [13]. By contrast
the same domains obtained from treatment-experienced
patients conferred increased AZT resistance in the context
of a WT polymerase domain by 3.6- to 5.8-fold and by 125- to
536-fold in the context of a polymerase domain encoding
TAMs. Mutational studies revealed the presence of several
connection domain mutations, including E312Q, G335C/D,
N348I, A360I/V, V365I, and A376S, that were associated with
AZT resistance [13]. In addition to changes in the connection
domain, the mutations H539N and D549N in the RNase H
domain have been shown to increase AZT resistance in a WT
genetic background and in combination with TAMs [14].
Finally, a recent study reported that A371V in the connection
domain and Q509L in the RNase H domain of HIV-1 RT were
selected in combination with TAMs when virus was passaged
under increasing concentrations of AZT [15]. Together, these
mutations enhance AZT resistance in the presence of TAMs
[15]. However, the in vivo signiﬁcance of the above-
mentioned studies is unknown.
In this study, we evaluated the in vivo relevance and role in
drug resistance of a common RT connection domain
mutation, N348I, using a variety of complementary ap-
proaches. The prevalence of N348I was evaluated in treated
versus therapy-naı ¨ve individuals; its order of appearance
relative to other drug resistance mutations was determined;
and its association with virological failure was compared with
other TAMs. The impact of N348I on decreased susceptibility
to AZT and NNRTIs was determined in cell culture-based
assays and further conﬁrmed in biochemical studies with
recombinant RT.
Methods
The British Columbia Centre for Excellence in HIV/AIDS
Drug Treatment Program
Plasma samples and clinical data were obtained from the
British Columbia Centre for Excellence in HIV/AIDS (the
Centre), which has been previously described in detail [16].
The Centre has been responsible for the distribution and the
population-based monitoring of antiretroviral treatment in
British Columbia since 1992. The majority of HIV-1–positive
men and women who have been treated are from Vancouver
and the surrounding region. Since 1986, over 7,000 HIV-1–
infected individuals have received antiretroviral treatment.
The Centre distributes antiretroviral drugs based on guide-
lines generated by the Therapeutic Guidelines Committee,
whose membership includes physicians, virologists, pharma-
cists, health service researchers, and economists. The Centre’s
HIV/AIDS drug treatment program has received ethical
approval from the University of British Columbia Ethics
Review Committee at its St. Paul’s Hospital site. The program
also conforms to the province’s Freedom of Information and
Protection of Privacy Act.
Data Collection
A detailed description of the collection method and
monitoring of data for HIV-1–positive individuals receiving
antiretroviral therapy in the Centre was published previously
[16]. The Centre recommends that viral load and CD4 cell
counts be monitored at baseline, at 4 wk after initiation of
antiretroviral therapy, and every 3 mo thereafter. Plasma
samples were stored and frozen at  20 8C. Viral load was
determined using the Roche Amplicor Monitor Assay (Roche
Diagnostics, Laval, Quebec, Canada) using either the standard
or ultrasensitive method (since 1999). CD4 counts were
measured by ﬂow cytometry, followed by ﬂuorescent mono-
clonal antibody analysis (Beckman Coulter, Mississauga,
Ontario, Canada). The Centre’s HIV genotypic drug resist-
ance database consists of over 25,000 samples. Genotypic
resistance testing was performed on stored plasma HIV RNA
samples [17–19]. HIV RNA extraction, RT-PCR ampliﬁcation,
PLoS Medicine | www.plosmedicine.org December 2007 | Volume 4 | Issue 12 | e335 1888
N348I Confers AZT and NNRTI Resistanceand DNA sequencing were performed as previously described
[16]. Results of the genotyping analysis were reported as
amino acid changes in the HIV-1 RT with respect to a WT
reference sequence (HIV-1 HXB2).
Prevalence of Mutations from Codons 240 to 400 in Drug-
Naı ¨ve and Experienced Individuals
Samples were analysed from individuals participating in
the HIV/AIDS Drug Treatment Program from 1996 to 2003.
The analysis was restricted to patient samples where
sequencing was performed up to codon 400 of the RT gene.
The latest available ‘‘on-therapy’’ sample was analysed for the
treatment-experienced individuals, while a baseline sample,
taken prior to therapy, was used for the therapy-naive
individuals. The treatment-experienced dataset was randomly
divided into two groups: a discovery test set of 500 individuals
and an independent validation set of 509 individuals. Samples
from 368 therapy naı ¨ve individuals were analysed to
determine the prevalence of mutations in the absence of
antiretroviral treatment.
Association of N348I with Key Drug Resistance Mutations
The last on-therapy sample from a total of 3,569 patients
was analysed for the association of N348I with key drug
resistance mutations (n¼161) compared to the prevalence of
key mutations in the absence of N348I (n ¼ 3,408). Key drug
resistance mutations were deﬁned as those listed by the
International AIDS Society-USA (IAS-USA) Drug Resistance
Mutations Group [9]. Only one sample was analysed for each
patient, and the samples that contained mixtures of WT and
mutant were treated as mutant.
Analysis of Drug Treatment Associated with Emergence of
N348I
The following baseline predictor variables were investi-
gated: age; gender; CD4 cell count; log10 transformed viral
load (pVL); prior exposure to NRTIs, NNRTIs, or protease
inhibitors (PIs); physician experience (per 100 patients); an
AIDS diagnosis; history of injection drug use; year of ﬁrst
therapy; and adherence. The analysis was restricted to
patients who were antiretroviral therapy naı ¨ve at baseline.
Estimates of adherence to antiretroviral therapy were based
on medications actually dispensed, not prescribed. For this
study, we limited our measure of adherence to the ﬁrst year of
therapy estimated by dividing the number of months of
medications dispensed by the number of months of follow-
up. This measure of adherence has been found to be
independently associated with HIV-1 viral suppression and
survival amongst HIV-1-infected persons enrolled in the HIV/
AIDS Drug Treatment Program [20,21]. Adherence was
categorised as 0% to ,40%, 40% to ,80%, 80% to ,95%,
and  95%. To determine which antiretroviral drug treat-
ment was associated with the emergence of N348I, an
explanatory logistic regression model was developed for
identifying which patient characteristics were most inﬂuen-
tial in the emergence of N348I during antiretroviral therapy.
A backward stepwise technique was used in the selection of
covariates. The selection of variables was based on two
criteria: Akaike Information Criterion (AIC) and Type III p-
values. These two criteria balance the model choice on
ﬁnding the best explanatory model (Type III p-values: lower p-
values indicate more signiﬁcance) and at the same time a
model with the best goodness-of-ﬁt statistic (AIC: lower values
indicate better ﬁt). AIC is a criterion that penalised larger
models, with equal ﬁt. It can be used to compare models of
different size, provided they are nested within each other. At
each step of this process, the AIC value and the Type III p-
values of each variable are recorded. Also at each step, the
variable with the highest Type III p-value is dropped until
there are no more variables left in the model. The ﬁnal model
is the model with the lowest AIC. The area under the ROC
(receiver operating characteristic) curve was used to measure
the model’s ability to discriminate between those who
developed resistance and those who did not [22].
Pattern of Appearance of N348I Early in Drug Therapy
This analysis was performed on a total of 31 individuals
who received treatment between June 1996 and February
2006. Neither N348I nor other key drug resistance mutations,
as deﬁned by the IAS-USA guidelines [9], were detected in the
viral genomes at the start of antiretroviral therapy. The time
in days after initiation of antiretroviral therapy of the ﬁrst
appearance of N348I and key drug resistance mutations was
determined. Samples that contained mixtures of both WT
and mutant at key codons were considered mutant. Where
N348I appeared at a time point immediately following its ﬁrst
appearance, any new key mutations, which had not appeared
previously, were also recorded.
Association of N348I and TAMs with Changes in Viral Load
This analysis was performed on data from 7,074 patients
from the BC Centre database between June 1996 and June
2007 where the change in viral load (DpVL) was deﬁned as
pVL at the time of the ﬁrst positive test for the mutation
subtracted by the pVL immediately before the ﬁrst positive
test for the mutation. The analysis was performed for N348I
and for each of the TAMs: M41L, D67N, K70R, L210W,
T215Y/F, and K219Q/E. The analysis excluded sequencing
data that were not performed up to codon 400 and did not
account for other IAS-USA deﬁned RT or PI drug resistance
mutations that may have been selected with N348I or TAMs.
Mixtures at each codon were considered positive for the
mutation. An upper (100,000 copies/ml) and a lower (500
copes/ml) cutoff for viral load were introduced into the
analysis to avoid introducing bias due to differences in
samples analysed using the original viral load assay (range 500
to 750,000 copies/ml) and the ultrasensitive viral load assay
(range 50 to 100,000 copies/ml).
Drugs and Reagents
The RT inhibitors AZT, 3TC, NVP, and EFV were obtained
from the AIDS Research and Reference Reagent Program,
National Institute for Allergy and Infectious Diseases, Na-
tional Institutes of Health (NIH). 39-Azido-29,39-dideoxythy-
midine triphosphate (AZT-TP) was purchased from TriLink
Biotechnologies. All other nucleotides were purchased from
GE Healthcare.
Cells
MT-2 cells [23] were cultured in RF-10 buffered with 25 mM
HEPES as previously described [24]. The TZM-bl indicator
cell line [25], obtained through the NIH AIDS Research and
Reference Reagent Program, and 293T cells were cultured in
DMEM-10 [26].
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Mutagenesis
The pDRNLXN construct (a gift from Johnson Mak) was
derived from the NL4.3 infectious molecular clone of HIV-1
[27] and was engineered with silent mutations that introduce
XbaI and NotI restrictions sites at nucleotides 2319 and 3938,
respectively. The pSVC21 construct contains the infectious
H X B - 2m o l e c u l a rc l o n eo fH I V - 1[ 2 8 ] .H I V - 1c l o n e s ,
containing mutations in the RT coding region, were
constructed by site-directed mutagenesis. Brieﬂy, pSK-Blue-
script II (Stratagene) with a 4.32-kb ApaI-SalI insert express-
ing the RT coding region from pDRNLXN or pSVC21 was
modiﬁed by site-directed mutagenesis using either the
QuikChange II Site Directed or QuikChange Multi Site
Directed Mutagenesis kits (Stratagene) according to manu-
facturer’s instructions. For mutations in the pNL4.3 back-
bone, full-length mutant infectious molecular clones of HIV-
1 were constructed by replacement of the XbaI-NotI frag-
ment in WT pDRNLXN with the modiﬁed XbaI-NotI
fragment obtained by site-directed mutagenesis. For pSVC21,
the WT ApaI-SalI insert was replaced with the same insert
containing the desired mutations(s). All HIV-1 constructs
were veriﬁed by nucleotide sequencing.
Generation of HIV-1 Stocks and Titration
HIV-1 virus stocks were generated by transfecting 239T
cells with infectious molecular clones of HIV-1 using the
calcium phosphate technique as previously described [29].
The resulting virus was concentrated by ultracentrifugation
through a 25% w/v sucrose cushion at 100,000g for 1 h at 4 8C.
The 50% tissue culture infective dose (TCID50) was deter-
mined by endpoint titration in MT-2 cells as previously
described [30] for HIV-1 stocks that were tested in drug
susceptibility assays performed in MT-2 cells. The virus titre
(in blue foci-forming units) was determined in TZM-bl cells as
described previously [29] for HIV-1 stocks that were tested in
drug susceptibility assays performed in TZM-bl cells.
Phenotypic Drug Susceptibility Assays
Drug susceptibility assays were performed in either MT-2
cells using cell viability as the readout [24,31] or TZM-bl cells
using the production of blue foci-forming cells as the
readout. In assays performed in MT-2 cells, 100 TCID50 of
appropriate virus was used to infect 6,000 cells in quad-
ruplicate wells of a 96-well plate. After 5- to 6-d incubation at
37 C and 5% CO2, cell viability, which was used to measure
the inhibitory effects of the drugs on virus-speciﬁc cytopathic
effects, was determined using the CellTiter 96 Aqueous One
Solution Cell Proliferation Assay according to manufacturer’s
instructions (Promega). For assays performed in the TZM-bl
indicator cell line, cells were seeded at 2 3 10
4 per well of a
96-well plate 24 h before infection. At 1 to 2 h prior to
infection, cultures were replaced with fresh DMEM-10 with or
without the appropriate RTI. Assays were performed in
quadruplicate wells. Virus was added to cells in the presence
of 10 lg/ml DEAE-dextran at an inoculum of 50–150 blue
foci-forming units per well. At 12–13 h postinfection, cells
were replaced with fresh DMEM-10 containing drug at the
appropriate concentration. After 48 h postinfection, cultures
were ﬁxed and stained for b-galactosidase activity as
previously described [29]. Assays were blinded and blue
foci-forming units were counted on an inverted microscope.
For each virus, the 50% inhibitory concentration (IC50) was
determined by the ‘‘sigmoidal dose-response, variable slope’’
nonlinear regression analysis of the percentage inhibition of
virus versus the log10 concentration of inhibitor using
GraphPad Prism for Windows (version 4.03) software (Graph-
Pad Software). Percentage inhibition of virus was calculated
at each drug concentration for assays performed in MT-2
cells as previously described [31]. The percentage inhibition
of HIV-1 replication at a given drug concentration in assays
performed in TZM-bl cells was calculated using the formula
[(x – y)/x] 3 100, where x is the mean blue foci-forming units
from four virus-only control wells and y is the mean blue foci-
forming units from four HIV-1–infected wells at a given drug
concentration.
Expression, Purification, and Characterisation of
Recombinant HIV-1 RT
The M41L, L210W, T215Y, and N348I mutations were
introduced into WT HIV-1LAI RT [32] by site-directed
mutagenesis using the QuikChange Mutagenesis kit. Full-
length sequencing of mutant RTs was performed to conﬁrm
the presence of the desired mutations. Recombinant WT and
mutant HIV-1 RT was overexpressed and puriﬁed to
homogeneity [33,34], and the enzyme’s active site concen-
trations were determined as described previously [35]. All
enzymes were found to exhibit similar levels of DNA
polymerisation activity (unpublished data). The sensitivity
of the WT and mutant enzymes to AZT-TP, NVP, and EFV
inhibition were determined under steady-state assay con-
ditions, as described previously [36,37].
Polyacrylamide Gel Electrophoresis Analysis of RT
Polymerisation Products Formed under Continuous DNA
Polymerisation Conditions
Heteropolymeric RNA-dependent or DNA-dependent
DNA polymerase template/primer (T/P) were prepared as
described previously [38]. DNA polymerisation reactions were
carried out by incubating 200 nM WT or mutant RT with 20
nM heteropolymeric T/P complex in 50 mM Tris-HCl (pH 8.0)
and 50 mM KCl for 5 min before the addition of 5 lM of each
dNTP, 2.5 lM AZT-TP, 3.0 mM ATP, and 10 mM MgCl2. After
deﬁned incubation periods, aliquots were removed from the
reaction tube and quenched with equal volumes of gel
loading dye. Products were separated by denaturing gel
e l e c t r o p h o r e s i sa n dq u a n t i ﬁ e dw i t haB i o - R a dG S 5 2 5
Molecular Imager.
Assay of RT-Catalysed Phosphorolysis of AZT-
Monophosphate Terminated Primers
A5 9
32P-labeled 26-nucleotide primer (59-CCTGTTCGGG
CGCCACTGCTAGAGAT-39) annealed to a 35-nucleotide
DNA template (59-AGAATGGAAAATCTCTAGCAGTGGC
GCCCGAACAG-39) or RNA template (59-AGAAUGGAAAAU
CUCUAGCAGUGGCGCCCGAACAG-39) was chain-termi-
nated with AZT-monophosphate (AZT-MP), as described
previously [39,40]. The phosphorolytic removal of AZT-MP
was achieved by incubating 200 nM active site RT with 20 nM
chain-terminated T/P complex in 50 mM Tris-HCl (pH 8.0)
and 50 mM KCl. The reaction was initiated by the addition of
3.0 mM ATP, 1 lM TTP, 5 lM ddCTP, and 10 mM MgCl2.
After deﬁned incubation periods, aliquots were removed
from the reaction tube and processed as described above.
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WT and mutant RT RNase H activity was evaluated using
the same AZT-MP chain-terminated RNA/DNA T/P substrate
described above, except the 59-end of the RNA was
32P-end-
labeled. Assays were carried out using 20 nM T/P, 3 mM ATP,
and 10 mM MgCl2 in a buffer containing 50 mM Tris-Cl (pH
8.0) and 50 mM KCl. Reactions were initiated by the addition
of 200 nM WT or mutant HIV-1 RT. Aliquots were removed,
quenched at varying times, and analysed as described above.
Statistical Analyses
Statistical analyses of the prevalence of mutations from
codons 240 to 400 in drug-naı ¨ve compared to drug-treated
individuals and the association of N348I with key drug
resistance mutations were performed using the Chi-square
test. In the descriptive analysis used to determine which
antiretroviral drug treatment was associated with the
emergence of N348I, categorical variables were compared
using the Chi-square or Fisher Exact test, and continuous
variables were compared using the Wilcoxon rank-sum test.
In the case of multiple comparisons, the Bonferroni and/or
the Benjamini and Hochberg methods were used [41–45],
although only the most signiﬁcant values are reported here.
For the analysis of the association of N348I and TAMs with
changes in viral load, the DpVL values were assessed for
normality as determined visually by normal probability plots
and by the one-sample Kolmogorov-Smirnov goodness-of-ﬁt
test. The one-sample t-test was used to test the alternative
hypothesis of the DpVL being equal to or less than 0 if DpVL
was normally distributed. If not normal, the DpVL values
were tested using the Wilcoxon rank-sum test. The statistical
signiﬁcance of differences between IC50 values obtained in
cell culture drug susceptibility assays was determined using
the Wilcoxon rank-sum test [46].
Results
N348I Is Prevalent in Patients after Antiretroviral Therapy
The prevalence of mutations at HIV RT codons 1–400
observed by population sequencing analysis of plasma-
derived HIV from individuals with known treatment histories
(n ¼ 1,009) was compared with their prevalence in samples
from therapy-naı ¨ve individuals (n ¼ 368). The treatment-
experienced dataset was divided randomly into two groups: a
discovery test set of 500 individuals and an independent
validation set of 509 individuals. N348I, a mutation located in
the connection domain of the RT, increased in prevalence
from below 1% in samples from untreated individuals to
greater than 12% in the discovery test and independent
validation subsets of samples from treated individuals (p¼7.7
3 10
 12) (Table 1). N348I was ranked as the ninth most
prevalent mutation of a total of 39 RT codons evaluated and
was more common than several ‘‘key’’ RTI mutations that are
used in genotypic resistance analyses; i.e. mutations at codons
210, 190, and 74 were ranked tenth, 16
th, and 18th,
respectively (unpublished data). Several other mutations
increased in prevalence signiﬁcantly in samples from RTI-
experienced individuals after adjustment for multiple com-
parisons using either the Bonferroni or Benjamini and
Hochberg methods. These include previously described novel
mutations in the polymerase domain [47] and mutations in
the RT connection domain at codons G359, A371, and K356
(ranked 13th, 20th and 27th, respectively). However, because
N348I was not polymorphic and was also the most prevalent
mutation in the RT connection domain, we concentrated on
characterising its role in RTI drug resistance.
Association of N348I with Known RT Drug Resistance
Mutations
To determine whether N348I was associated with the
presence of other IAS-USA-deﬁned RTI resistance mutations,
we analysed the last on-therapy sample from 161 patients
with N348I compared with 3,408 without N348I. N348I was
highly associated with several key drug resistance mutations,
including M184V/I (p¼6.6310
 45) the TAMs M41L (p¼1.83
10
 14), D67N (p¼7.7310
 10), K70R (p¼1.4310
 10), T215Y/F
(p ¼ 6.0 3 10
 21), K219Q/E (p ¼ 8.0 3 10
 4), and L210W (p ¼
0.002), and the NNRTI resistance mutations K103N (p¼1.13
10
 19), V108l (p ¼ 8.4 3 10
 13), Y181C/I (p ¼ 4.7 3 10
 13) and
G190A/S (p ¼ 8.0 3 10
 9) (Figure 1). While all TAMs were
signiﬁcantly associated with N348I, there was a stronger
association with mutations at codons 41, 67, 70, and 215 that
emerge early in drug therapy compared with mutations at
codons 210 and 219 that tend to appear late in therapy [48].
Table 1. Prevalence of RT Mutations in Treated and Untreated Patients
Rank
a RT Mutation p-Value (Test) p-Value (Validation) Prevalence
(Untreated) (%)
Prevalence
(Treated) (%)
Increase (%)
1 M184V 3.0 3 10
 60 1.6 3 10
 62 1.6 54.6 53.0
2 T215Y/F 2.4 3 10
 31 2.1 3 10
 31 1.9 34.2 32.3
3 M41L 2.2 3 10
 25 4.3 3 10
 25 1.6 28.4 26.8
4 D67N 2.3 3 10
 20 2.1 3 10
 21 1.6 24.5 22.8
5 K219Q 1.5 3 10
 15 3.1 3 10
 17 0.5 17.8 17.3
6 Y181C 1.4 3 10
 14 4.9 3 10
 17 0.5 17.2 16.7
7 K70R 2.3 3 10
 14 1.2 3 10
 15 0.8 17.0 16.2
8 K103N 8.6 3 10
 13 4.6 3 10
 13 2.7 18.7 16.0
9 N348I 1.0 3 10
 08 7.7 3 10
 12 0.8 12.1 11.3
10 L210W 2.5 3 10
 09 9.1 3 10
 10 4.1 17.4 13.4
aThe top ten most prevalent mutations are listed from a total of 39 RT codons where changes were identified to be more prevalent in treated compared to untreated individuals.
doi:10.1371/journal.pmed.0040335.t001
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The association of N348I with several baseline predictor
variables was analysed. Univariate analyses demonstrated a
signiﬁcant association with male gender (odds ratio [OR] 2.23,
95% conﬁdence interval [CI] 1.21–4.13), increased adherence
(OR 1.13, 95% CI 1.05–1.22), and increased physician’s
experience (OR 1.24, 95% CI 1.03–1.48), AZT treatment
(OR 1.60, 95% CI 1.07–2.40), and NVP treatment (OR 1.53,
95% CI 1.02–2.29). The association of predictor variables with
N348I was analysed by multivariate logistic regression
analysis. These data demonstrate that treatment with AZT
compared with treatment that did not consist of either AZT
or NVP was associated with an increased risk for N348I, while
there was no increased risk for N348I with NVP treatment
compared with treatment with neither AZT nor NVP (Table
2). However, combined treatment with AZT and NVP was
associated with a 2.62-fold increased risk in the emergence of
N348I compared with treatment regimens containing neither
drug (Table 2). Other variables associated with increased risk
of emergence of N348I following multivariate analysis
included increased adherence and physician’s experience.
In contrast, there was a negative association with N348I and
treatment initiation taking place between 2000 and 2003 (OR
0.58, 95% CI 0.35–0.98) or between 2003 and 2005 (OR 0.27,
95% CI 0.10–0.78) relative to patients starting before 2000,
perhaps due to the fact that prescription of combination
therapy with AZT and NVP has been less frequent after the
year 2000.
Pattern of Emergence of N348I Early in Drug Therapy
In order to determine whether N348I appears early in drug
therapy and its pattern of emergence with respect to key drug
resistance mutations, we performed an analysis on samples
from a subset of patients in the Centre’s database who had
neither N348I nor other IAS-USA-resistance mutations
present at baseline and for whom complete treatment history
and viral data were known. Of the 31 patients ﬁtting these
criteria, we observed that N348I tended to appear in plasma
virus relatively early after initiation of antiretroviral therapy.
Moreover, the appearance of N348I was observed during
virological failure (viral loads 283–591,000 copies/ml, median
3,600). In general, N348I appeared at the same time as
M184V/I and before the appearance of TAMs (Figure 2).
N348I also usually appeared at the same time as key NNRTI
resistance mutations (Figure 2). Notably, N348I was the ﬁrst
mutation that was observed in two patients (patients 5 and 16,
with viral loads of 1,120 and 591,000 copies/ml, respectively)
indicating an association with virological failure.
Appearance of N348I Is Associated with a Concomitant
Increase in Viral Load at Least Equivalent to That Seen
with TAMs
To determine the potential in vivo signiﬁcance of N348I,
we examined whether the appearance of N348I was associated
with an increase in viral load and compared this with the
changes in viral load associated with each of the other TAMs
(Table 3). Our analysis demonstrated that the appearance of
N348I was associated with a signiﬁcant median increase in
pVL of 0.23 log10 copies/ml (p , 0.001) and that this increase
was at least as large as the DpVL associated with each of the
individual TAMs: M41L, D67N, K70R, L210W, T215Y/F, and
K219Q/E (Table 3). These data indicate that the appearance
of N348I is associated with an increase in viral load that is at
least as large as that observed with any of the IAS-USA-
deﬁned TAMs. However, this analysis could not exclude the
contribution of key PI or RT mutations that might have
appeared simultaneously with the speciﬁc mutations being
evaluated, due to the large number of possible permutations.
N348I Confers Reduced Susceptibility to AZT in a WT
Backbone and When Combined with TAMs
The impact of N348I on AZT susceptibility was examined
by introducing this mutation by site-directed mutagenesis
into the molecular clones HXB-2 (HX/348) and NL4.3 (NL/
348) in order to evaluate the effect of N348I in two genetically
distinct WT backbones. Phenotypic susceptibility assays were
performed in MT-2 cells for the HXB-2 strain (HX) or in the
TZM-bl indicator cell line for NL4.3 strain (NL). In
comparison with the WT HIV-1, both the HX/348 (p ¼ 0.05,
n ¼ 3) and NL/348 (p ¼ 0.005, n ¼ 8) mutant viruses
demonstrated 2-fold decreased susceptibility to AZT (Table
4). In contrast, NL/348 showed no signiﬁcant difference in
3TC susceptibility compared with WT NL (1-fold, p . 0.2, n¼
5) (Table 4). Because N348I is highly associated with TAMs
(Figure 1), we also introduced N348I into molecular clones
that contained M41L and T215Y (NL/2AZT þ 348) or M41L,
L210W, and T215Y (HX/3AZT þ 348) and assayed for AZT
susceptibility (Table 4). NL/2AZTþ348 demonstrated a 2-fold
decrease in AZT susceptibility compared with NL/2AZT (p ¼
0.047, n¼6) (Table 4), whereas HX/3AZTþ348 demonstrated
a 4.0-fold decrease in AZT susceptibility compared with HX/
3AZT (p¼0.05, n¼3). Taken together, these data demonstrate
that N348I, alone and in combination with TAMs, confers
AZT resistance.
N348I Decreases 3TC Susceptibility in the Context of TAMs
Although N348I did not appear to confer 3TC resistance by
itself, when combined with M41L and T215Y (NL/2AZT þ
348), it conferred a 3.3-fold and 1.8-fold decrease in 3TC
susceptibility compared to the WT (p ¼ 0.005, n ¼ 5) and NL/
2AZT (p ¼ 0.008, n ¼ 5) viruses, respectively (Table 4). These
data are consistent with a previous report demonstrating that
Figure 1. Association of N348I with Key Drug Resistance Mutations
The prevalence of key drug resistance mutations without N348I (red
bars) compared to their prevalence with N348I (blue bars). The last on
therapy sample from a total of 3,569 patients was analysed where 3,408
and 161 samples did not or did contain N348I, respectively. Statistically
significant differences between the two groups were determined by Chi-
square analysis. The asterisk above the bars denotes p , 0.001, except
for L210 where p ¼ 0.002.
doi:10.1371/journal.pmed.0040335.g001
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N348I Confers AZT and NNRTI ResistanceTAMs confer decreased susceptibility to 3TC [49] and
indicate that N348I further potentiates 3TC resistance in
the context of TAMs. As expected, M184V conferred high-
level resistance to 3TC. However, the impact of N348I on
enhancing 3TC resistance in the context of M184V in either
the absence or presence of the TAM combination M41L and
T215Y could not be assessed as the 3TC IC50 values were
beyond the detectable limits of our assay (Table 4). Never-
theless, any possible potentiating effect of N348I on 3TC
resistance is unlikely to be clinically relevant given the high
level of resistance conferred by M184V alone [50–52].
N348I Does Not Counteract Antagonism between M184V
and TAMs
M184V suppresses phenotypic resistance conferred by
TAMs, although the effect decreases with an increase in the
number of TAMs [53]. Because M184V appears with N348I
and TAMs during virological failure (Figure 2), it is possible
that N348I might be involved in facilitating dual AZT/3TC
resistance in viruses that harbour both TAMs and M184V.
Accordingly, we compared the AZT susceptibility of HIV-1
containing M184V and TAMs (M41L and T215Y) (NL/2AZTþ
184) and HIV-1 containing M184V, TAMs, and N348I (NL/
2AZTþ184þ348). The data did not demonstrate a signiﬁcant
increase in the AZT IC50 for NL/2AZTþ184þ348 compared
with NL/2AZT þ 184 (1.3-fold, p . 0.2, n ¼ 3) (Table 4),
suggesting that N348I does not counteract the antagonistic
effects of M184V on phenotypic AZT resistance.
N348I Confers Decreased Susceptibility to NNRTIs
Since N348I is also highly associated with key mutations
that confer NNRTI resistance (Figures 1 and 2), we
investigated whether N348I could decrease susceptibility to
NVP and EFV. Remarkably, viruses harbouring N348I
conferred signiﬁcant decrease in NVP (7.4-fold) (p ¼ 0.005,
n ¼ 5) and EFV (2.5-fold) (p ¼ 0.005, n ¼ 5) susceptibilities
(Table 5). Similar to previous studies [54], K103N conferred
resistance to both NVP (96-fold) and EFV (30-fold) (Table 5).
Notably, when N348I was combined with K103N, we observed
a signiﬁcant potentiation of EFV resistance by N348I (7.5-
fold) (p ¼ 0.005, n ¼ 5), resulting in HIV-1 that was highly
resistant to EFV (226-fold) (Table 5). N348I also potentiated
NVP resistance conferred by K103N, although we could not
determine the exact level of enhancement as the IC50 value
was greater than what could be measured in our assay. These
data clearly demonstrate that N348I not only confers AZT
resistance but also decreases susceptibility to NNRTIs.
Furthermore, N348I also conferred EFV and NVP resistance
at the enzyme level (Table 6).
Biochemical Mechanisms of AZT Resistance by
Recombinant HIV-1 RT Containing N348I
NRTI-associated resistancem u t a t i o n sc a nb eb r o a d l y
categorised into two groups depending on their phenotypic
mechanism of resistance [1]. TAMs augment the ability of
HIV-1 RT to excise a chain-terminating NRTI-monophos-
phate from a prematurely terminated DNA chain [55–57]. In
comparison, mutations such as K65R, K70E, L74V, Q151M,
and M184V increase the selectivity of RT for incorporation of
natural deoxynucleoside triphosphate substrate versus the
NRTI-triphosphate [1]. To deﬁne the biochemical mechanism
by which the N348I mutation in HIV-1 RT confers resistance
to AZT, we designed and performed independent experi-
ments that assessed whether N348I, alone or in combination
with M41L, L210W, and T215Y (3AZT), conferred AZT
resistance by a discrimination or excision phenotype.
Our data show that each of the four recombinant enzymes
(WT, N348I, 3AZT, and 3AZT þ N348I) was equally sensitive
to inhibition by AZT-TP (Table 6), suggesting that N348I does
not confer AZT resistance by a discrimination phenotype.
Accordingly, the ability of the WT and mutant enzymes to
excise AZT-MP from a chain-terminated primer was eval-
uated in two different experiments. In the ﬁrst, we analysed
steady-state synthesis by both WT and mutant enzymes in the
presence of AZT-TP and ATP, using a heteropolymeric RNA
or DNA template, corresponding to the HIV-1 sequence used
for (–) strong stop DNA synthesis, primed with a DNA
oligonucleotide [58]. The 173-nucleotide incorporation
events needed to produce full-length DNA product in this
assay system allow for multiple AZT-TP incorporation and
AZT-MP excision events during the formation of full-length
ﬁnal product. Figure 3A shows that in the presence of 3 mM
ATP, the 3AZT and 3AZT þ N348I RTs synthesised
signiﬁcantly greater amounts of full-length DNA on the
DNA/DNA T/P than either the WT or N348I enzymes.
However, no signiﬁcant differences were noted between the
3AZT and 3AZTþN348I enzymes (Figure 3A). By contrast, on
the RNA/DNA T/P, the 3AZT þ N348I enzyme synthesised
greater amounts of full-length DNA product than any of the
other enzymes (Figure 3B).
To further determine the role of N348I in the AZT excision
phenotype, we next evaluated the ability of the WT or mutant
RT to excise AZT-MP from the 3’ terminus of the primer and
to rescue DNA synthesis, as described previously [40,55].
These data show a similar trend to that observed in the
steady-state assays (Figure 4A and 4B). The 3AZT and 3AZTþ
N348I RT were more efﬁcient at excising AZT-MP and
rescuing DNA synthesis than either the WT or N348I enzymes
on a DNA/DNA T/P, but no signiﬁcant differences were noted
between the 3AZT and 3AZT/N348I enzymes (Figure 4A).
However, on the RNA/DNA T/P, the 3AZT þ N348I enzyme
exhibited a greater capacity to excise AZT-MP than the 3AZT
enzyme (Figure 4B). Taken together, these data suggest that
the N348I mutation augments the AZT excision phenotype
on an RNA/DNA T/P but not on a DNA/DNA T/P.
To further characterise this phenotype, we also assessed the
RNase H cleavage events that occurred during the AZT-MP
excision reactions described in the latter experiment. This
Table 2. Association of N348I with Specific Drug Therapy
Drug Patients without
N348I (n ¼ 1,303),
n (%)
Patients with
N348I (n ¼ 104),
n (%)
OR
a (95%
Confidence
Interval)
No AZT or NVP 403 (30.9) 18 (17.3) 1.0
AZT and no NVP 285 (21.9) 26 (25.0) 2.21 (1.17–4.16)
NVP and no AZT 301 (23.1) 26 (25.0) 1.82 (0.97–3.43)
AZT and NVP 314 (24.1) 34 (32.7) 2.62 (1.43–4.81)
aOR estimates were adjusted for gender, adherence, physician’s experience, and year of
initiation of antiretroviral therapy.
doi:10.1371/journal.pmed.0040335.t002
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combination with 3AZT, signiﬁcantly decreased RNase H
cleavage activity; and in particular, decreased formation of a
secondary cleavage product that reduced the RNA template
to 17 nucleotides (the corresponding RNA/DNA duplex
length is reduced to ten nucleotides) (Figure 4C). The
signiﬁcance of this decreased RNase H cleavage activity is
discussed later.
Discussion
In this study, we demonstrate a role of the commonly
selected N348I mutation in the connection domain of HIV-1
RT in both NRTI (AZT) and NNRTI (NVP and EFV)
resistance. N348I is more prevalent in clinical samples from
patients treated with RTIs compared with samples from
treatment-naı ¨ve individuals. In this regard, our analysis ranks
N348I as the ninth most prevalent resistance mutation from a
total of 39 different RT codons that were evaluated in RTI
experienced patients and this mutation was observed more
frequently in our cohort than mutations at codons 210, 69, 44,
190, 118, and 74, most of which have been the topic of
multiple clinical, genetic, virological, biochemical and struc-
tural analyses [59–63]. As expected with HIV, there was a
strong codon bias, with most of the mutant N348I (98.6%)
encoded by ATT, while more than 97% of WT N348 was
encoded by AAT. Furthermore, the N348I mutation is
associated with M184V/I, TAMs, K103N and Y181C and is
selected by NVP and AZT treatment. The N348I mutation
also appears relatively early in virological failure, generally
before the appearance of TAMs and usually at the same time
as the acquisition of NNRTI resistance mutations. Notably,
N348I was the ﬁrst mutation observed in two patients in our
cohort. The early appearance of N348I after initiation of
antiretroviral therapy is consistent with it playing a key role
in the development of RTI resistance rather than being an
accessory mutation that appears after primary mutations [64].
This is supported by our ﬁndings that its appearance is
Figure 2. Pattern of Emergence of N348I Early in Drug Therapy Failure
The pattern of emergence of N348I relative to key drug resistance mutations in the RT is shown with respect to days post therapy. These patients had
neither N348I nor key drug resistance mutations present at baseline. Mixtures of WT and mutants were considered mutant in this analysis. The presence
of the indicated key mutations was included from data available from each time point up to the appearance of N348I. If subsequent time points also
contained N348I, then the key mutations present at this time point was also included in the analysis.
doi:10.1371/journal.pmed.0040335.g002
Table 3. Appearance of N348I and TAMs Is Associated with an Increase in Viral Load
Patient Status Mutations Selected
M41L D67N K70R L210W T215Y/F K219Q/E N348I
Total with previral load (N) 528 413 354 284 550 272 330
First quartile (DpVL)  0.063  0.073  0.086  0.109  0.077  0.076  0.019
Median (DpVL)
a 0.163 0.162 0.170 0.102 0.130 0.146 0.230
Third quartile (DpVL) 0.560 0.574 0.600 0.427 0.533 0.593 0.655
Missing
b (N) 237 160 124 155 252 92 41
No resistance
c (N) 6,309 6,501 6,596 6,635 6,272 6,710 6,703
Total number of patients ¼ 7,074.
aMedian DpVL defined as pVL at the time of the first positive test for the mutation subtracted by the pVL immediately before the first positive test for the mutation. DpVL for N348I and
each of the TAMs was significant (p , 0.001).
bDenotes no previous viral load data available for a patient.
cDenotes no IAS-USA-defined drug resistance mutation at indicated codon.
doi:10.1371/journal.pmed.0040335.t003
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N348I Confers AZT and NNRTI Resistanceassociated with an increase in viral load, which is at least as
large as that observed for any of the other TAMs.
The high prevalence of N348I is not unique to the Centre’s
database as it was also identiﬁed in a separate analysis of
mutations beyond RT codon 240 in a large US clinical
database (Quest Diagnostics) [65]. In the latter study, two sets
of sequences were analysed. The ﬁrst comprised 41,122 de-
identiﬁed clinical samples collected between January 2002
and June 2003 and the second comprised 16,449 samples
collected between July 2003 and December 2003. Viruses with
at least one resistance mutation in the protease or RT (64.8%
in dataset 1 and 57% in dataset 2) were compared with those
that contained no key drug resistance mutations (35.2%,
dataset 1). The frequency of N348I in the ﬁrst and second
datasets was 13.6% and 13.0%, respectively. A recent study
also demonstrates the presence of N348I in RT sequences
from over 3,000 treated individuals with subtype B HIV-1 in a
UK database [66]. Thus, the prevalence of N348I in three
large databases indicates that this mutation is likely to be
present in other clade B cohorts receiving antiretroviral
therapy.
To delineate the role of N348I in RTI resistance, this
mutation was introduced into molecular HIV-1 clones with
deﬁned genetic backbones. In this regard, N348I, alone or in
combination with TAMs, conferred 2- to 4-fold AZT
resistance. The level of AZT resistance conferred by N348I
alone is comparable to the levels of resistance conferred by
other individual TAMs. For example, the M41L mutation has
been reported to confer between 1.4- to 4-fold AZT
resistance, the K70R mutation up to 8-fold resistance, and
T215Y up to 16-fold resistance [59,60,62,67,68]. Furthermore,
other groups have also recently demonstrated that the N348I
mutation confers both AZT and NNRTI resistance; with the
Monogram group reporting a 2.4-fold change in AZT
susceptibility [69], while another group reported a 23-fold
change in AZT susceptibility [70]. In addition, a recent study
Table 5. Effect of N348I on NNRTI Resistance
Strain Amino Acid at Indicated RT Codon
a Nevirapine Efavirenz
103 348 Mean IC50 6 SE (lM)
b Resistance (Fold)
c Mean IC50 6 SE (lM) Resistance (Fold)
NL K N 0.10 6 0.01 1 0.003 6 0.0003 1
NL/348 — I 0.72 6 0.04 7.4 0.007 6 0.0007 2.5
NL/103 N — 9.3 6 2.7 96 0.08 6 0.01 30
NL/103þ348 N I .15 .154 0.59 6 0.08 226
aRT amino acid residues shown are numbered as for NL4.3 and are those that differ from the sequence of NL4.3.
bIC50 and standard error values were determined in drug susceptibility assays performed in the TZM-bl indicator cell line from at least three independent assays. The differences between
the IC50 values of NVP for NL and NL/348 (p¼0.005, n¼5) and the IC50 values of EFV for NL and NL/348 (p¼0.005, n¼5) and NL/103 and NL/103þ348 (p¼0.005, n¼5) were statistically
significant.
cIC50 for mutant strain divided by IC50 for corresponding WT strain. Values of .1 indicate resistance.
doi:10.1371/journal.pmed.0040335.t005
Table 4. Effect of N348I on AZT and 3TC Resistance
Strain Amino Acid at Indicated RT Codon
a AZT 3TC
41 184 210 215 348 Mean IC50 6 SE
(lM)
b
Resistance (Fold)
c Mean IC50 6 SE
(lM)
d
Resistance (Fold)
c
HX M M L T N 0.05 6 0.004 1 ND
e —
HX/348 — — — — I 0.10 6 0.03 2 ND —
HX/3AZT L — W Y — 3.3 6 0.85 66 ND —
HX/3AZTþ348 L — W Y I 13.0 6 6.1 260 ND —
N L — ————0 . 1 0 6 0.01 1 0.60 6 0.07 1
NL/348 — — — — I 0.19 6 0.02 2 0.62 6 0.04 1
NL/2AZT L — — Y — 1.5 6 0.12 14 1.1 6 0.15 1.8
NL/2AZT þ 348 L — — Y I 3.0 6 0.60 28 2.0 6 0.26 3.3
NL/184 — V — — — 0.07 6 0.01 0.7 .50 .84
NL/184þ348 — V — — I 0.10 6 0.01 0.9 .50 .84
NL/2AZTþ184 L V — Y — 0.80 6 0.11 7.6 .50 .84
NL/2AZTþ184þ348 L V — Y I 1.0 6 0.22 9.6 .50 .84
aRT amino acid residues shown are numbered as for HXB-2 and NL4.3 and are those that differ from WT sequences.
bIC50 and standard error values were determined in drug susceptibility assays performed in MT-2 cells for HX clones and in the TZM-bl indicator cell line for NL clones from at least three
independent assays. The differences between the IC50 values of AZT for HX and HX/348 (p¼0.05, n¼3), NL and NL/348 (p¼0.005, n¼8), HX/3AZT and HX/3AZTþ348 (p¼0.05, n¼3), and
NL/2AZT and NL/2AZTþ348 (p¼0.047, n¼6) were statistically significant. The difference in AZT IC50 values for NL/2AZTþ184 and NL2/AZTþ184þ348 (p . 0.2, n¼3) was not statistically
significant.
cThe difference between the 3TC IC50 valuesfor mutant strain divided by IC50 for corresponding WT strain. Values of .1 indicate resistance.
dThe 3TC IC50 values for NL/2AZT and NL/2AZTþ348 (p¼0.008, n¼5) were statistically significant. The difference between the 3TC IC50 values for NL and NL/348 (p . 0.2, n¼5) were not
statistically significant.
eNot done.
doi:10.1371/journal.pmed.0040335.t004
PLoS Medicine | www.plosmedicine.org December 2007 | Volume 4 | Issue 12 | e335 1895
N348I Confers AZT and NNRTI Resistancedemonstrated that reversion of N348I to the WT codon in an
RT gene from an isolate derived from an RTI-experienced
patient increased AZT sensitivity 5- to 10-fold [13]. Interest-
ingly, N348I also conferred decreased susceptibility to EFV
and NVP, data that are also consistent with studies from other
groups [69,70]. In our cohort N348I was associated with the
appearance of K103N, V108l, Y181C/I, and G190A/S early in
virological failure (Figure 2) and was signiﬁcantly associated
with these mutations in analysis of the entire database (Figure
1). N348I signiﬁcantly potentiated EFV and NVP resistance
when combined with K103N. Consistent with our cell
culture–based assays, NNRTI resistance was also observed at
the enzyme level with recombinant RT expressing N348I.
Furthermore, the phenotypic ﬁndings are consistent with our
clinical data demonstrating the signiﬁcant association of
N348I with TAMs and NNRTI mutations and its selection in
patients on AZT and NVP combination therapy.
N348I was also signiﬁcantly associated with M184V/I in our
cohort. N348I conferred a small increase in 3TC resistance in
the context of TAMs but did not counteract the previously
observed antagonism between M184V and TAMs. This is in
contrast to another connection domain mutation, G333D/E,
which is associated with dual resistance to AZT and 3TC [10].
It is curious that our data demonstrate a strong association of
N348I with M184V/I despite it having little effect on drug
susceptibility in the context of M184V. However, this can be
explained by several possibilities, including that M184V/I and
N348I are not genetically linked, that their coincident
emergence is due to a high proportion of the Centre’s cohort
being prescribed 3TC, or that N348I has an effect on M184V/I
that is independent of decreasing drug susceptibility such as
altering viral ﬁtness. Further studies will be needed to address
these possibilities.
Apart from Q145M, which has been reported to confer
broad resistance to several NRTIs and NNRTIs [71,72], and
Y181C/I, which may confer resistance to stavudine in addition
to NVP [73,74], N348I represents the only other example of
an in vivo mutation that confers decreased susceptibility to
two classes of RT inhibitors. However, in contrast to N348I,
the prevalence of Q145M in an Italian cohort of 3,595
patients was lower (2.36%) and was always found in the
presence of key drug resistance mutations [72]. In our cohort,
Q145M was exceedingly rare with a prevalence of less than
0.5%. Additional studies also demonstrate that Q145M
signiﬁcantly decreases viral replication capacity and that
the recombinant enzyme displays a large loss in catalytic
efﬁciency [72]. While the effect of N348I on viral replication
ﬁtness has not been established, recombinant enzymes
harbouring this mutation facilitate DNA synthesis reactions
at least as efﬁciently as the WT enzyme (unpublished data).
Biochemical analyses designed to elucidate the mechanism
by which N348I confers AZT resistance indicate that this
Figure 3. Steady-State DNA Synthesis by WT and Mutant HIV-1 RT in the
Presence of AZT-TP and 3 mM ATP
The experimental conditions for this experiment are described in
Methods.
(A) DNA synthesis was evaluated on a DNA/DNA T/P.
(B) DNA synthesis was evaluated on an RNA/DNA T/P.
For both (A) and (B), lanes demarcated as 1–4 included control reactions
for the WT, N348I, 3AZT, and 3AZT þ N348I RTs where all substituents
were added except ATP. The primer, final product, and AZT-MP chain-
termination sites are indicated.
doi:10.1371/journal.pmed.0040335.g003
Table 6. Drug Susceptibility of Recombinant RT to AZT-TP and
NNRTIs
RT NRTI/NNRTI IC50 (lM)
a Resistance (Fold)
WT
b AZT-TP 0.32 6 0.11 —
N348I
c AZT-TP 0.36 6 0.08 1.1
3AZT
d AZT-TP 0.44 6 0.12 1.4
3AZTþ348I
e AZT-TP 0.32 6 0.06 1.0
WT Nevirapine 4.63 6 1.02 —
N348I Nevirapine 14.25 6 4.22 3.1
WT Efavirenz 0.0148 6 0.0011 —
N348I Efavirenz 0.0348 6 0.0009 2.4
WT Delavirdine 2.01 6 0.58 —
N348I Delavirdine 3.42 6 0.82 1.7
a50% Inhibitory concentration 6 standard deviation.
bWT recombinant RT derived from LAI backbone.
cRT expressing the N348I mutation in LAI backbone.
dRT expressing the TAMs M41L þ L210W þ T215Y in LAI backbone.
eRT expressing TAMs in described in footnote d and N348I in LAI backbone.
doi:10.1371/journal.pmed.0040335.t006
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N348I Confers AZT and NNRTI Resistancemutation, consistent with other TAMs, acts by an excision
rather than discrimination phenotype. However, an increase
in AZT excision was only observed with a RNA/DNA T/P and
not with a DNA/DNA T/P. Recently, it was suggested that
mutations in the RT that decrease RNase H activity will
enhance the AZT excision phenotype by slowing down the
rate at which the RNA template strand is degraded [13,14]. In
this regard, our analyses conﬁrm that the N348I mutation,
alone and in combination with TAMs, decreases the enzyme’s
RNase H activity. In particular, the mutation signiﬁcantly
reduces the appearance of a 17-nucleotide secondary
cleavage product, which corresponds to RNA/DNA duplex
length of ten nucleotides. Recent studies that were designed
to delineate the relationship between T/P duplex length and
efﬁciency of AZT excision demonstrated that RT could not
efﬁciently unblock chain-terminated T/P if the RNA/DNA
duplex length was less than 13 nucleotides [75]. Thus, the
decrease in the formation of this cleavage product is
signiﬁcant and suggests a possible mechanism by which
N348I confers AZT resistance. The structural mechanism by
which N348I confers AZT (and NNRTI) resistance, however,
cannot be inferred from this study. Recent studies have
demonstrated that mutations in the RNase H primer grip
region can signiﬁcantly enhance AZT resistance by changing
interactions between RT and the T/P complex and/or shifting
the balance between the polymerase and RNase H activities
[15,76]. In contrast, N348I does not make direct contacts with
the T/P. Furthermore, N348 in p66 RT is 27 A ˚ away from the
polymerase active site and 20 A ˚ from the NNRTI-binding
pocket, while N348 in p51 RT is 60 A ˚ from the NNRTI-
binding pocket (Figure 5). Interestingly, N348 in p66 lies in
close proximity to I270 and P272 at the base of the thumb
domain in some crystal structures, suggesting a possible
mechanism by which N348I mediates AZT resistance [77].
Nevertheless, additional biochemical and structural studies
are warranted to deﬁne the exact mechanism by which N348I
confers RTI resistance.
One of the major limitations of this study is that while the
data demonstrate that the appearance of N348I is associated
with an increase in viral load, which is at least as large as the
recognised TAMs, it does not account for the simultaneous
appearance of other key PI or RT drug resistance mutations
that could also contribute to the observed increase in viral
load. Nevertheless, this caveat also applies to our analysis of
the individual TAMs. Even with this large study, the number
of permutations of mutations is too large to be able to
exclude the contribution of other mutations, particularly as
these patients are on combination therapy. Nevertheless, this
study represents, to our knowledge, the most thorough
evaluation of the in vivo relevance of a drug resistance
mutation that can contribute to HIV drug resistance, but is
not presently included in most genotypic and phenotypic
resistance assays.
In conclusion, we have demonstrated that a mutation in the
connection domain of the HIV-1 RT, N348I, is prevalent in
Figure 4. Isotherms for ATP-Mediated Phosphorolytic Excision of AZT-MP
by WT, 3AZT, N348I, and 3AZT þ N348I
HIV-1 RT on DNA/DNA T/P (A) and RNA/DNA T/P (B). Data are the mean
of three or four independent experiments. Autoradiogram of RNase H
products generated during ATP-mediated excision assays on the RNA/
DNA T/P (C). Experiments were carried out as described in Methods.
doi:10.1371/journal.pmed.0040335.g004
Figure 5. Position of N348 in the HIV-1 RT Structure
Structural model of HIV-1 demonstrating the position of N348 in the p66
(blue) and p51 RT (pink) subunits relative to the polymerase active site
(gold spheres), the NNRTI-binding pocket (green) and the dimer interface
(gold). N348 in p66 (red sphere) is located in the connection domain and
is in close proximity to the hinge region of the p66 thumb (turquoise). In
contrast, N348 in p51 is located far from the dimer interface. The RT
coordinates were derived from 1RTD [78], with C280 reverted to WT S280
and with missing residues of p51 added (amino acids 218 to 230 and 430
to 440), while the DNA/DNA duplex was converted to an RNA/DNA
duplex. The image was prepared using POVRAY (Persistence of Vision
Pty, Ltd, Williamstown, Victoria, Australia) and GNU Image Manipulation
Program (GIMP) (http://www.gimp.org/).
doi:10.1371/journal.pmed.0040335.g005
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N348I Confers AZT and NNRTI Resistancedrug-treated individuals, appears relatively early in drug
therapy, and confers decreased susceptibility to AZT and
NNRTIs. The mechanism of AZT resistance can be ascribed to
increased nucleotide excision, as observed from an RNA/DNA
T/P, and is likely to be manifested through decreased RNase H
activity conferred by N348I. Decreased susceptibility to
NNRTIs can be demonstrated at the enzyme level. Taken
together, our data underscore the important role of N348I in
conferring drug resistance to AZT and NNRTIs.
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N348I Confers AZT and NNRTI ResistanceEditors’ Summary
Background. In the 1980s, infection with the human immunodeficiency
virus (HIV), which causes acquired immunodeficiency syndrome (AIDS),
was a death sentence. Although the first antiretroviral drugs (com-
pounds that block HIV’s life cycle) were developed quickly, single
antiretrovirals only transiently suppress HIV infection. HIV rapidly
accumulates random changes (mutations) in its genetic material, some
of which make it drug resistant. Nowadays, there are many different
antiretrovirals. Some inhibit the viral protease, an enzyme used to
assemble new viruses. Others block reverse transcriptase (RT), which
makes replicates of the genes of the virus. Nucleoside/nucleotide RT
inhibitors (NRTIs; for example, zidovudine—also called AZT—and
lamivudine) and non-nucleoside RT inhibitors (NNRTIs; for example,
nevirapine and efavirenz) interfere with the activity of RT by binding to
different sites in its so-called ‘‘DNA polymerase domain,’’ the part of the
enzyme that constructs copies of the viral genes. Highly active
antiretroviral therapy (HAART), which was introduced in the mid 1990s,
combines several antiretrovirals (usually a protease inhibitor and two
NRTIs or an NNRTI and two NRTIs) so that the replication of any virus that
develops resistance to one drug is inhibited by the other drugs in the
mix. When treated with HAART, HIV infection is usually a chronic, stable
condition rather than a fatal disease.
Why Was This Study Done? Unfortunately, HIV that is resistant to drugs
still develops in some patients. To improve the prevention and
management of drug resistance, a better understanding of the
mutations that cause resistance is needed. Resistance to RT inhibitors
usually involves mutations in the DNA polymerase domain that reduce
the efficacy of NRTIs (including thymidine analogue mutations—also
known as TAMs—and lamivudine-resistance mutations) and NNRTIs.
Blood tests that detect these resistance mutations (genotype tests) have
been used for several years to guide individualized selection of HIV
drugs. Recently, however, mutations outside the DNA polymerase
domain have also been implicated in resistance to RT inhibitors. In this
study, the researchers have used data and samples collected since the
mid 1990s by Canada’s British Columbia Centre for Excellence in HIV/
AIDS to investigate the clinical relevance of a mutation called N348I. This
mutation changes an asparagine (a type of amino acid) to an isoleucine
in a region of RT known as the connection domain. The researchers have
also investigated how this mutation causes resistance to RT inhibitors in
laboratory tests.
What Did the Researchers Do and Find? The researchers analyzed the
first two-thirds of the RT gene in viruses isolated from a large number of
the Centre’s patients. Virus carrying the N348I mutation was present in
less than one in 100 patients whose HIV infection had never been
treated, but in more than one in 10 treatment-experienced patients. The
mutation appeared early in therapy, often in viruses that had TAMs, a
lamivudine-resistance mutation called M184V/I, and/or NNRTI resistance
mutations. Patients treated with zidovudine and nevirapine were 2.6
times more likely to have the N348I mutation than patients not treated
with these drugs. Furthermore, the appearance of the N348I mutation
often coincided with an increase in viral load, although other mutations
that appeared at a similar time could have contributed to this increase.
When the researchers introduced the N348I mutation into HIV growing
in the laboratory, they found that it decreased the susceptibility of the
virus to zidovudine and to NNRTIs.
What Do These Findings Mean? These findings show that the
treatment of patients with RT inhibitors can select a drug-resistant HIV
variant that has a mutation outside the enzyme’s DNA polymerase
domain. Because this N348I mutation, which is commonly selected in
vivo and has also been seen in other studies, confers resistance to two
classes of RT inhibitors and can emerge early during therapy, it could
have a large impact on patient responses to antiviral regimens that
contain zidovudine and nevirapine. Although these findings do not show
that the N348I mutation alone causes treatment failure, they may have
implications for genotypic and phenotypic resistance testing, which is
often used to guide treatment decisions. At present, genotype tests for
resistance to RT inhibitors look for mutations only in the DNA
polymerase domain of RT. This study is the first to demonstrate that it
might be worth looking for the N348I mutation (and for other mutations
outside the DNA polymerase domain) to improve the ability of genotypic
and phenotypic resistance tests to predict treatment outcomes.
Additional Information. Please access these Web sites via the online
version of this summary at http://dx.doi.org/10.1371/journal.pmed.
0040335.
  Information is available from the US National Institute of Allergy and
Infectious Diseases on HIV infection and AIDS
  HIV InSite has comprehensive information on all aspects of HIV/AIDS,
including links to fact sheets (in English, French, and Spanish) about
antiretrovirals, and chapters explaining antiretroviral resistance testing
  NAM, a UK registered charity, provides information about all aspects of
HIV and AIDS, including fact sheets on types of HIV drugs, drug
resistance, and resistance tests (in English, Spanish, French, Portu-
guese, and Russian)
  The US Centers for Disease Control and Prevention provides
information on HIV/AIDS and on treatment (in English and Spanish)
  AIDSinfo, a service of the US Department of Health and Human
Services provides information for patients on HIV and its treatment
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